论文部分内容阅读
自杀基因疗法(suicide gene therapy)又称为酶药物前体法(enzyme prodrug therapy),自1986年首次报道单纯疱疹病胸苷激酶(herpeslsimplex virus-thymidine kinase,HSV-TK)因可提高抗病毒药物更昔洛韦(gancyclovir,GCV)对肿瘤细的杀伤敏感性后,自杀基因疗法就成为众多研究者争先探索焦点。HSV-TK/GCV目前是研究最深入、最具有应用前景自杀基因治疗系统,现已广泛用于各种恶性肿瘤的治疗,本就HSV-TK/GCV自杀基因系统的靶向治疗和与放射治疗联合应用的研究进展作一综述。
Suicide gene therapy, also known as enzyme prodrug therapy, was first reported in 1986 as a result of herpeslsimplex virus-thymidine kinase (HSV-TK) As gancyclovir (GCV) has been shown to kill tumor sensitivity, suicide gene therapy has become the focus of many investigators. HSV-TK / GCV is currently the most advanced and promising suicide gene therapy system and has been widely used in the treatment of various malignancies. The HSV-TK / GCV targeted therapy of HSV-TK / GCV suicide gene system and the combination of radiation therapy The research progress of combined application is reviewed.